http://www.apotex.com/ca/en/about/press/default.aspThe latest news from apotex.ca, APOTEX Canada: Advancing GenericsSat, 4 Feb 2012 08:49:18 GMTCopyright 2012, Apotex Inc.en-ca60http://www.apotex.com/ca/en/about/press/20111208.aspApotex Inc., announced that on December 6, 2011, the Federal Court of Canada ruled in favour of Apotex, clearing the way to deliver their generic version of Plavix®, Apo-Clopidogrel, to the Canadian market. Apotex challenged the Sanofi-aventis Plavix® patents for over 8 years, through two Federal Court systems and multiple levels of judicial review including the Supreme Court of Canada.Thu, 8 Dec 2011 9:00:00 GMThttp://www.apotex.com/ca/en/about/press/20111101.aspApotex Inc., the largest Canadian owned pharmaceutical company, launched today Apo-Esomeprazole, a generic version of AstraZeneca's Nexium®, a gastric proton pump inhibitor (PPI). With initial launches to the provinces of Québec, Nova Scotia, New Brunswick, and Ontario, Apotex has now released product to the remainder of the Canadian market. The brand product costs the public and private healthcare budgets close to $300 million per year.Tue, 1 Nov 2011 9:00:00 GMThttp://www.apotex.com/ca/en/about/press/20111011.aspApotex Inc. is pleased to announce its latest successful patent challenge, clearing the way to deliver a generic alternative to Xalatan® to the Canadian market. Following a favorable decision at the Court of Appeal, Apo-Latanoprost was released to the Canadian market on October 3rd 2011, nearly three years prior to patent expiry.Wed, 11 Oct 2011 9:00:00 GMThttp://www.apotex.com/ca/en/about/press/20110914.aspOn September, 14, 2011, an FDA Advisory Committee voted in favour of approving Ferriprox in the US for patients who have iron overload from blood transfusions, when other chelators are inadequate. This is a major achievement for ApoPharma and the first NDA for the Apotex companies.Wed, 14 Sep 2011 9:00:00 GMThttp://www.apotex.com/ca/en/about/press/20110727.aspCanada and the European Union (EU) are currently negotiating a comprehensive economic and trade agreement (CETA), which is expected to be concluded by 2012. As part of these negotiations, the EU has tabled proposals that would lengthen the period of market exclusivity for brand-name drugs in Canada by an average of 3.5 years and add nearly $3-billion annually to Canada's prescription drug bill.Wed, 27 Jul 2011 9:00:00 GMThttp://www.apotex.com/ca/en/about/press/20110510.aspApotex, one of the largest generic pharmaceutical manufacturers in the world, announced it will soon resume shipments of its oral solid dose products to the U.S. market. The announcement comes on the heels of a Food and Drug Administration (FDA) decision to lift its import alert at Apotex's largest solid dose manufacturing facility supplying product to the US.Tues, 10 May 2011 9:00:00 GMThttp://www.apotex.com/ca/en/about/press/20110308.aspToronto, ON - Apotex Inc, Canada's largest pharmaceutical company, today underscored the need for Members of Parliament to fix Canada's Access to Medicines Regime (CAMR) by passing Bill C-393 when it comes up for final vote tomorrow, March 9, 2011. This bill will ensure that CAMR is streamlined and strengthened, and that more affordable life-saving drugs can get to developing countries where thousands of people are dying daily from treatable illnesses.Tues, 8 Mar 2011 9:00:00 GMThttp://www.apotex.com/ca/en/about/press/20100803.aspToronto, ON - Apotex Inc, announced today the sale of more than 40 pharmaceutical products to AA Pharma, a company headquartered in Toronto. Both companies are privately held and no value of the sale was provided. These products represent different therapeutic categories and the sale takes effect as of August 3rd, 2010.Tues, 3 Aug 2010 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20100519.aspToronto, ON - Apotex Inc, a Canadian owned pharmaceutical company with headquarters in Toronto, launched today Apo-Atorvastatin, a generic version of 'Lipitor®' produced by Pfizer®. This is the largest product to be genericized in Canadian history with approximate yearly sales of $1.2 billion. This last patent on Lipitor® will not expire until 2022. Apotex Inc. invented its own crystal form, thus overcoming the patents, 12 years ahead of time, which will result in close to $7 billion of cost-savings for the Canadian healthcare system.Wed, 19 May 2010 10:00:00 GMThttp://www.apotex.com/ca/en/about/press/20100121.aspToronto, ON - The shipment of medicines included painkillers and antibiotics and is slated to leave this Saturday on an Air Canada flight. An earlier shipment left with a group of 10 doctors working for the relief organization "Feed the Children". The shipment of medicines included painkillers and antibiotics and is slated to leave this Saturday on an Air Canada flight. An earlier shipment left with a group of 10 doctors working for the relief organization "Feed the Children".Thurs, 21 Jan 2010 09:30:00 GMThttp://www.apotex.com/ca/en/about/press/20091020.aspWeston, FL - Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain. The Fentanyl Transdermal System, developed by Hisamitsu, is manufactured at the company's state of the art Carlsbad, California facility. The total Fentanyl patch market in the U.S. represents approximately $1.2 billion in sales.Tues, 20 Oct 2009 09:30:00 GMThttp://www.apotex.com/ca/en/about/press/20090918.aspToronto, ON - Apotex Inc. today announced that the second shipment of Apo-TriAvir, the generic triple-combination AIDS drug produced to simplify AIDS treatment in developing countries, was leaving for Rwanda, the only country to have benefited from Canada's Access to Medicines Regime (CAMR). CAMR was created by Parliament more than 5 years ago, but because of the costly and complicated process it requires, no other company has come forward to participate in producing more affordable, life-saving generic drugs for export to developing countries.Fri, 18 Sep 2009 09:30:00 GMThttp://www.apotex.com/ca/en/about/press/20090917.aspToronto, ON - This communiqué is an update to Health Canada's press release of today's date (7:16 p.m.) relating to three of Apotex's products, Apo-Amilzide (5-50 mg), Apo-Meloxicam (7.5 & 15 mg) and Apo- Ranitidine (75 & 150 mg).Thurs, 17 Sep 2009 09:30:00 GMThttp://www.apotex.com/ca/en/about/press/20090908.aspToronto, ON - Apotex today issued the following statement concerning an Import Alert issued by the US Food and Drug Administration: The Import Alert recently posted by FDA applies to products manufactured at 2 of Apotex's many facilities. This alert relates to observations made following routine audits for products destined to the US only. We are actively working with the FDA to resolve the identified concerns as quickly as possible, and are optimistic that there will be a prompt resolution.Tues, 8 Sep 2009 09:30:00 GMThttp://www.apotex.com/ca/en/about/press/20090514.aspToronto, ON - Apotex Inc, the largest Canadian-owned pharmaceutical company, reiterated the need to fix the Canada's Access to Medicines Regime (CAMR) if more affordable life-saving drugs are to get to developing countries where thousands of people are dying daily. The regime has not been successful in attaining its original objectives as declared when the law creating it (the Jean Chrétien Pledge to Africa) was passed five years ago this month.Wed, 14 May 2009 09:30:00 GMThttp://www.apotex.com/ca/en/about/press/20081212.aspWeston, FL - Apotex Corp. announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) in the case of Bristol Myers Squib/Sanofi v. Apotex, Inc. has found that U.S. Patent 4,847,265 (the '265 patent) covering Plavix® is valid and enforceable. The ruling upholds the U.S. District Court for the Southern District of New York's June 2007 decision regarding the '265 patent. The '265 patent covers clopidogrel bisulfate, the active ingredient in Plavix®. Apotex will simultaneously pursue a rehearing / rehearing en banc of today's decision.Fri, 12 Dec 2008 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20080507.aspToronto, ON - Apotex Inc., Canada's largest generic pharmaceutical company has successfully bid and been awarded a tender from the Rwandan Government for the life saving triple combination AIDS drug "Apo Triavir". Apotex is the first company to provide this medicine to Africa under the provisions of the Canadian Access to Medicines Regime (CAMR).Wed, 7 May 2008 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20080501.aspToronto, ON - A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex Inc. of Canada in collaboration with Intas Biopharmaceuticals Limited (IBPL) of India. Neukine®, a recombinant granulocyte colony stimulating factor (G-CSF) is already manufactured and marketed in India and other countries by IBPL. Kwizda Pharma of Austria had been working with IBPL to develop G-CSF for the European market for some time.Thu, 1 May 2008 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20071205.aspToronto, ON - Apotex Inc., announced today that it has acquired Lareq Pharma S.L. of Spain for an undisclosed sum from Industria Quimica Y Farmaceutica VIR S.A. Lareq, founded in 1984 and dedicated to generics since 1996, is a mid-sized generic pharmaceutical company. With 12 generic registrations, several pending near-term launches and products in development, Lareq is the 13th largest player in the retail pharmacy generics segment.Wed, 5 Dec 2007 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20071115.aspToronto, ON - Apotex Inc., the largest Canadian-owned generic company announced today the purchase from Zambon of the pharmaceutical company, Topgen, E.S.V. of Belgium, No acquisition price was disclosed. Topgen, headquartered in Brussels, is the 7th largest generic pharmaceutical company in this country with approximately 30 generic registrations and has a nation-wide sales force that reaches over 4,000 doctors and 3,000 pharmacies.Wed, 15 Nov 2007 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20070920.aspToronto, ON - The Federal Commissioner of Patents issued today a compulsory licence for ApoTriavir under Canada's Access to Medicines Regime Program (CAMR) allowing Apotex to proceed with manufacturing of the product. This drug, a triple combination AIDS therapy, was the first product to be approved by Health Canada under the provisions of the CAMR. ApoTriavir was approved by Health Canada in August 2006 and is pre-qualified by the World Health Organization.Thu, 20 Sep 2007 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20070829.aspWoodcliff Lake, NJ - Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc., has received approval from the Therapeutic Products Directorate (TPD) of Health Canada for its Abbreviated New Drug Submission (ANDS) for its Portia® generic oral contraceptive as a generic equivalent of Wyeth Laboratories' Min-Ovral® Tablets. This represents the first approval of a generic oral contraceptive for Canadian consumers.Thu, 29 Aug 2007 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20070524.aspWeston, FL - Apotex Corp. announced today that it has launched amlodipine besylate tablets (2.5 mg, 5 mg, and 10 mg), the generic equivalent of Pfizer's Norvasc®. The launch follows Monday's issuance of the mandate by the US Court of Appeals for the Federal Circuit's decision of March 22 invalidating Pfizer's US Patent 4,879,303 (the '303 patent) covering amlodipine besylate. The decision came in an action brought by Pfizer against Apotex. Apotex successfully invalidated the Pfizer patent.Thu, 24 May 2007 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20070321.aspWeston, FL - Apotex Corp. announced today the Federal Circuit Court of Appeals in the case of Pfizer, Inc. v. Apotex, Inc. reversed a trial court's ruling and found that Pfizer's U.S. Patent 4,879,303 (the '303 patent) covering the Pfizer product Norvasc® was invalid. The '303 patent covers amlodipine besylate the active ingredient in Norvasc® as well as tablets made from amlodipine besylate. Because the limiting patent expires in two days, no company will have exclusivity over the product. Apotex expects to launch the product in the very near future.Wed, 21 Mar 2007 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20060831.aspWeston, FL - Apotex Corp. today announced that the U.S. District Court of the Southern District of New York has granted the request of Bristol Myers Squibb and Sanofi to issue a preliminary injunction to prevent further sales of Apotex's generic version of Sanofi's Plavix® (clopidogrel 75mg tablets). The Court denied BMS and Sanofi's request to force Apotex to recall product it has already shipped.Thu, 31 Aug 2006 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20060808.aspWeston, FL - Apotex Corp. announced that it has today launched clopidogrel bisulfate 75 mg tablets. Clopidogrel is the generic equivalent of Sanofi's Plavix®, which is marketed in the U.S. by Bristol Myers Squibb.Tue, 8 Aug 2006 17:00:00 GMThttp://www.apotex.com/ca/en/about/press/20060125.aspWeston, FL - Apotex Corp. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel bisulfate 75 mg tablets.Wed, 25 Jan 2006 17:00:00 GMT